Exelixis, Inc.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an…
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2019-06-04 | Donna E. Shalala · D-FL | House | Sold | $1,001 - $15,000 |
| 2019-04-16 | Donna E. Shalala · D-FL | House | Sold | $1,001 - $15,000 |
| 2019-02-06 | Donna E. Shalala · D-FL | House | Bought | $1,001 - $15,000 |
| 2019-01-09 | Donna E. Shalala · D-FL | House | Bought | $1,001 - $15,000 |
Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.